Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

NCT03563794 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

T2DM

Interventions

DRUG: CSII+Vildagliptin
DRUG: CSII(insulin Lispro)

Sponsor

The First Affiliated Hospital of Xiamen University